Abstract
Point-of-care (POC) systems that can quantify critical physiological parameters can enable better diagnostics and better treatment strategies. Currently available techniques do not easily lend themselves to miniaturized automated systems for POC applications. Many of the current sensing systems cannot be applied at POC due to constraints of portability, cost, analysis time, and requirement of highly skilled personnel to operate the systems.
Florida International University researchers developed a technology that uses disposable biosensors to detect an analyte on an electrochemical biosensing platform for the detection of biomolecules at point-of-care (POC). The technology is based on binding agent-analyte interaction that provides the specific and selective detection of a target analyte. The device is portable and measures the concentration of an analyte in fluids. The device has been tested for the detection of cortisol in biological fluids.
The binding agent of the electrochemical sensor can be a binding protein, an antibody, or an aptamer, and the analyte can be a biomolecule, for example a hormone, a protein, a polysaccharide, a lipid, a polynucleotide, or a metabolite, and the fluid can be a biofluid. The technology can also be used for detecting the presence of a disease or assessing the likelihood of development of the disease associated with abnormal levels of a biomolecule of interest.
Benefit
Highly sensitive.Portable, miniaturized, and automated system to use at point-of-care.Low cost, rapid analysis time, and requires small sample volume.
Market Application
Portable device for Point-of-Care applications for measuring concentration of an analyte in biological fluids. Facilitates the detection of diseases affected by cortisol or assessing the likelihood of developing Addison’s disease, Cushing’s syndrome, adrenal insufficiencies, psychological stress, or posttraumatic stress disorder. The biosensor can be adapted for the detection and monitoring of several disease conditions.
Brochure
